Shots: Pacira acquires MyoScience, in all stock transaction for $220M. MyoScience to receive $120M upfront and $100M as regulatory and commercial milestones. The transaction is expected to close in Apr’2019 The focus of an acquisition is to strengthen Pacira’s footprints in post-surgical analgesics by adding Myoscience’s iovera system to Pacira’s lead candidate Exparel Pacira is […]Read More
Tags : Pacira
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US